Recurrent Glioblastoma Clinical Trial Pipeline Analysis: 45+ Key Companies Shaping the Future of Recurrent Glioblastoma Therapeutics | DelveInsight

DelveInsight's Recurrent Glioblastoma Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline Recurrent Glioblastoma therapies in various stages of clinical development. The report provides insights into 45+ companies and 50+ pipeline drugs in the Recurrent Glioblastoma pipeline landscape, covering clinical and nonclinical stage products, therapeutic assessments, and inactive pipeline products.

Key takeaways from the Recurrent Glioblastoma Clinical Trial Landscape Report

• DelveInsight's Recurrent Glioblastoma pipeline report depicts a robust space with 45+ companies working to develop 50+ pipeline therapies for Recurrent Glioblastoma treatment.
• Key Recurrent Glioblastoma companies such as Telix Pharmaceuticals (Innovations) Pty Limited, Sichuan Baili Pharmaceutical Co., Ltd., VAXIMM AG, Cue Biopharma, Revolution Medicines, Inc., BioNTech SE, Ascletis Pharmaceuticals Co., Ltd., Sichuan Honghe Biotechnology Co., Ltd., Shanghai Simnova Biotechnology Co.,Ltd., Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd., Beijing Immunochina Medical Science & Technology Co., Ltd., BeyondBio Inc., Chimeric Therapeutics, KATMAI Pharmaceuticals, CNS Pharmaceuticals, Inc., and others.
• Promising Recurrent Glioblastoma pipeline therapies in various stages of development include TLX-101-Tx + Lomustine, BL-B01D1, VXM01, CUE-102, RMC-5552, BNT327, ASC40, KH617, SNC109, BC008-1A, WL276 CAR-T cells, BEY1107, CHM-1101 CAR-T cells, KTM-101, Berubicin, and others.

Request a sample and discover the recent advances in Recurrent Glioblastoma treatment drugs https://www.delveinsight.com/sample-request/recurrent-glioblastoma-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

What is Recurrent Glioblastoma?

Recurrent glioblastoma is the return of glioblastoma, an aggressive and high-grade primary brain tumor, after initial treatment such as surgery, radiation, and chemotherapy. It is one of the most challenging cancers to treat due to its highly invasive nature and tendency to infiltrate surrounding brain tissue. Even after optimal therapy, recurrence is common because microscopic tumor cells often remain undetected.
The prognosis for recurrent disease is generally poor, and management focuses on prolonging survival while maintaining quality of life.
The signs and symptoms of recurrent glioblastoma are similar to those seen at initial diagnosis but may be more severe or progressive. Patients commonly experience persistent headaches, seizures, nausea and vomiting due to increased intracranial pressure. Neurological deficits such as weakness, speech difficulties, memory loss, or personality changes may also occur, depending on the tumor's location.
The pathophysiology of recurrent glioblastoma involves rapid tumor cell proliferation, resistance to therapy, and genetic mutations that promote survival and invasion. Tumor cells exhibit abnormal signaling pathways, increased angiogenesis, and the ability to evade apoptosis. A key feature is tumor heterogeneity, meaning different populations of cancer cells respond differently to treatment.
Diagnosis of recurrent glioblastoma typically involves imaging studies such as MRI with contrast, which helps identify tumor regrowth and differentiate it from treatment-related changes like radiation necrosis. Advanced imaging techniques and clinical evaluation may be required, and in some cases, biopsy or repeat surgery may be performed to confirm recurrence.
Treatment is complex and individualized. Options may include repeat surgical resection, re-irradiation, and chemotherapy with agents such as Temozolomide or targeted therapies such as Bevacizumab. Supportive care, including anti-epileptic drugs and corticosteroids, is important for symptom control. Emerging approaches such as immunotherapy and clinical trials offer potential benefits for some patients.

Emerging Recurrent Glioblastoma Drug Profiles

TLX-101-Tx + Lomustine: Telix Pharmaceuticals (Innovations) Pty Limited
TLX101 is a novel approach that is readily able to pass through the blood-brain barrier, the normal protective barrier that prevents many potential drug candidates from entering the brain. TLX101-Tx is an investigational radiopharmaceutical therapy being evaluated in combination with lomustine versus lomustine alone in adult patients with first recurrence of glioblastoma.
TLX101 targets L-type amino acid transporter 1 (LAT-1), which is typically over-expressed in glioblastoma, and delivers targeted radiation to glioblastoma cells. Currently, the drug is in Phase III for the treatment of recurrent glioblastoma.

BL-B01D1: Sichuan Baili Pharmaceutical Co., Ltd.
BL-B01D1 is the world's first and only clinical-stage EGFR × HER3 bispecific ADC. The bispecific structure is designed to target a wide range of solid tumors and achieve greater enrichment within tumor tissues, thereby enhancing tumor killing activity and reducing on-target off-tumor toxicity.
BL-B01D1 is a potentially first-in-class bispecific ADC developed by SystImmune, targeting both EGFR and HER3. It comprises a proprietary bispecific antibody and linker-payload containing a stable, cleavable linker and a topoisomerase inhibitor. Currently, the drug is in Phase II stage of development for the treatment of recurrent glioblastoma.

VXM01: VAXIMM AG
VXM01 is an oral immunotherapy that activates T-cells against VEGFR2, a key validated protein in tumor vasculature. By activating this process, VXM01 aims to abolish tumor blood supply while enabling infiltration of immune cells with broad anti-tumor effects.
VXM01 carries vascular endothelial growth factor receptor-2 (VEGFR2), which is highly overexpressed on tumor vasculature and certain cancer cells, as the target gene. VXM01 has also received orphan designation from the European Commission and the U.S. Food and Drug Administration for glioblastoma. Currently, the drug is in Phase II stage of clinical development for recurrent glioblastoma.

Learn more about the novel and emerging Recurrent Glioblastoma pipeline therapies https://www.delveinsight.com/sample-request/recurrent-glioblastoma-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Scope of the Recurrent Glioblastoma Pipeline Report

• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Phase III, Phase II, Phase I, Preclinical, Discovery
• Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical
• Therapeutics Assessment By Molecule Type: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy
• Key Recurrent Glioblastoma Companies: Telix Pharmaceuticals (Innovations) Pty Limited, Sichuan Baili Pharmaceutical Co., Ltd., VAXIMM AG, Cue Biopharma, Revolution Medicines, Inc., BioNTech SE, Ascletis Pharmaceuticals Co., Ltd., Sichuan Honghe Biotechnology Co., Ltd., Shanghai Simnova Biotechnology Co.,Ltd., Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd., Beijing Immunochina Medical Science & Technology Co., Ltd., BeyondBio Inc., Chimeric Therapeutics, KATMAI Pharmaceuticals, CNS Pharmaceuticals, Inc.
• Key Recurrent Glioblastoma Pipeline Therapies: TLX-101-Tx + Lomustine, BL-B01D1, VXM01, CUE-102, RMC-5552, BNT327, ASC40, KH617, SNC109, BC008-1A, WL276 CAR-T cells, BEY1107, CHM-1101 CAR-T cells, KTM-101, Berubicin.

Dive deep into rich insights for new drugs for Recurrent Glioblastoma treatment, visit https://www.delveinsight.com/sample-request/recurrent-glioblastoma-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents

1. Recurrent Glioblastoma Pipeline Report Introduction
2. Recurrent Glioblastoma Pipeline Report Executive Summary
3. Recurrent Glioblastoma: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Recurrent Glioblastoma Pipeline Therapeutics
6. Recurrent Glioblastoma Pipeline: Late Stage Products (Phase III)
7. Recurrent Glioblastoma Pipeline: Mid Stage Products (Phase II)
8. Recurrent Glioblastoma Pipeline: Early Stage Products (Phase I)
9. Recurrent Glioblastoma Pipeline: Preclinical and Discovery Stage Products
10. Recurrent Glioblastoma Pipeline Therapeutics Assessment
11. Inactive Products in the Recurrent Glioblastoma Pipeline
12. Key Companies
13. Key Products in the Recurrent Glioblastoma Pipeline
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

For further information on the Recurrent Glioblastoma pipeline therapeutics, reach out https://www.delveinsight.com/sample-request/recurrent-glioblastoma-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Media Contact
Company Name: DelveInsight
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +1-469-945-7679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, DelveInsight offers customized research solutions and insights to clients across the globe.

This release was published on openPR.